Argininosuccinate synthetase-1 (ASS-1), a rate-limiting enzyme in de novo arginine biosynthesis, has been reported to be downregulated in hepatocarcinoma and prostate cancer, as well as in malignant melanoma [20,21,22] and to be associated with advanced tumor stages and poor survival rates [22]. This evidence concerns the gene ASS1 and melanoma.